Preview Mode Links will not work in preview mode

This Week in Cardiology

Oct 28, 2022

ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Follow-up on ERASE AF

II. Recreational Drugs

Four Commonly Abused Drugs Linked With Atrial Fibrillation

III. Etripamil

RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT

- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

IV. Misuse of Science

When Bad Actors Hijack Good Research

- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review

V. Diabetes as a Risk Factor

Diabetes Becoming Less Potent Risk Factor for CVD Events

- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact